Active Ingredient(s): Opicapone
FDA Approved: * April 24, 2020
Pharm Company: * NEUROCRINE
Category: Parkinsons

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Ongentys Overview

Opicapone, sold under the brand name Ongentys, is a medication which is administered together with levodopa in people with Parkinson's disease.[4] The most common side effects are dyskinesia (difficulty controlling movement), constipation, increased blood creatine kinase, hypotension/syncope, and decreased weight.[3][5] Opicapone, works to restore the levels of dopamine in the parts of the brain that control movement and coordination.[4&...

Read more Ongentys Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Ongentys Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 25mg, 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ongentys: (2 results)

Sorted by National Drug Code
  • 70370-3025 Ongentys 25 mg Oral Capsule by Neurocrine Biosciences, Inc.
  • 70370-3050 Ongentys 50 mg Oral Capsule by Neurocrine Biosciences, Inc.

Other drugs which contain Opicapone or a similar ingredient: (1 result)